Regarding Bcl-xL and sensitivity to TRAIL, we recently revealed that sensitivity of a panel of pancreatic cancer cell lines to TRAIL was inversely correlated with their Bcl-xL expression [16]. This evidence concerns the gene BCL2L1 and familial pancreatic carcinoma.